In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
0:04 - Intro
0:37 - ESMO 2023 Presentation on Dato-DXd in NSCLC
1:15 - Methods/Design of TROPION-Lung01
2:35 - Efficacy End Points
4:20 - Questions on Actionable Genomic Alterations
4:59 - Overall Survival Analyses
5:53 - Safety Findings
7:45 - ILD Events
8:45 - Overview of Findings
10:14 - Takeaways for Community Oncologists
12:42 - Next Steps for Dato-DXd
15:14 - Closing Thoughts
In season 4, episode 20 of Targeted Talks, Aaron Lisberg, MD, a thoracic medical oncologist at the University of California, Los Angeles (UCLA), delves into findings from the phase 3 TROPION-Lung01 study (NCT04656652) of datopotamab deruxtecan (Dato-DXd; DS-1062a) for the treatment of patients with advanced or metastatic non–small cell lung cancer (NSCLC).
Dato-DXd is a Trop-2 directed antibody drug conjugate. In the phase 3, open-label, global study, Dato-DXd was compared with docetaxel for the treatment of this patient population. Patients were randomly assigned in a 1:1 fashion to receive Dato-DXd 6 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks.
According to findings presented at the 2023 ESMO Congress, Dato-DXd led to a statistically significant improvement in progression-free survival (PFS) for the treatment of patients with advanced or metastatic NSCLC. However, patients with squamous histology did not experience a benefit, suggesting differences in how these cancer types respond to this treatment.
Although TROPION-Lung01 revealed a PFS advantage among patients with non-squamous lung cancer, the occurrence of grade 3 or higher interstitial lung disease (ILD) highlights the importance of cautious monitoring and strict adherence to ILD management guidelines for all patients receiving this Dato-DXd.
“The take home here was that Dato-DXd was a better tolerated drug from a global perspective, although there are some clear differences in terms of toxicity profile. It appears to be a potential new, meaningful therapy for patients with non-squamous metastatic advanced non–small cell lung cancer eligible for second-line chemotherapy,” said Lisberg.
Overall, the TROPION-Lung01 data suggest that non-squamous histology might be a key predictor of response to this therapy. Further research is needed to understand this disparity and tailor treatment strategies accordingly.
REFERENCE:
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
